MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation - divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation

Osteoarthritis and Cartilage

Volumn 18, Issue 3, 2010, Pages 279-288

  Sondergaard, B C ^a   Schultz, N ^a   Madsen, S H ^a   Bay Jensen, A C ^a   Kassem, M ^b   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Aggrecanase; Articular cartilage; Cartilage degradation; Cartilage metabolism; Catabolic enzymes; Cell signaling pathways; Enzyme pathways; Matrixmetalloprotinase; Mitogen activated protein kinases (MAPKs); Osteoarthritis

Indexed keywords

AGGRECANASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; GELATINASE; GELATINASE A; GELATINASE B; HYDROXYPROLINE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ONCOSTATIN M; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR;

ANIMAL TISSUE; CARTILAGE DEGENERATION; COLORIMETRY; CONTROLLED STUDY; COW; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TOXICITY TESTING; ZYMOGRAPHY;

ANIMALS; CARTILAGE, ARTICULAR; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; SIGNAL TRANSDUCTION; STATISTICS AS TOPIC;

EID: 76549091830     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2009.11.005     Document Type: Review

References (44)

1. Kiani C., Chen L., Wu Y.J., Yee A.J., and Yang B.B. Structure and function of aggrecan. Cell Res 12 1 (2002 Mar) 19-32
2. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.L., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434 7033 (2005 Mar 31) 644-648
3. Glasson S.S., Askew R., Sheppard B., Carito B.A., Blanchet T., Ma H.L., et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 50 8 (2004 Aug) 2547-2558
4. East C.J., Stanton H., Golub S.B., Rogerson F.M., and Fosang A.J. ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan. J Biol Chem 282 12 (2007 Mar 23) 8632-8640
5. Stanton H., Rogerson F.M., East C.J., Golub S.B., Lawlor K.E., Meeker C.T., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434 7033 (2005 Mar 31) 648-652
6. Fosang A.J., Last K., Stanton H., Weeks D.B., Campbell I.K., Hardingham T.E., et al. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J Biol Chem 275 42 (2000 Oct 20) 33027-33037
7. Fosang A.J., Last K., Fujii Y., Seiki M., and Okada Y. Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain. FEBS Lett 430 3 (1998 Jul 3) 186-190
8. Fosang A.J., Last K., and Maciewicz R.A. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 98 10 (1996 Nov 15) 2292-2299
9. Schaller S., Henriksen K., Hoegh-Andersen P., Sondergaard B.C., Sumer E.U., Tanko L.B., et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol 3 5 (2005 Oct) 553-580
10. Sondergaard B.C., Henriksen K., Wulf H., Oestergaard S., Schurigt U., Brauer R., et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 14 8 (2006 Aug) 738-748
11. Oestergaard S., Sondergaard B.C., Hoegh-Andersen P., Henriksen K., Qvist P., Christiansen C., et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 54 8 (2006 Aug) 2441-2451
12. Billinghurst R.C., Wu W., Ionescu M., Reiner A., Dahlberg L., Chen J., et al. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum 43 3 (2000 Mar) 664-672
13. Billinghurst R.C., Dahlberg L., Ionescu M., Reiner A., Bourne R., Rorabeck C., et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 99 7 (1997 Apr 1) 1534-1545
14. Fosang A.J., Neame P.J., Last K., Hardingham T.E., Murphy G., and Hamilton J.A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 267 27 (1992 Sep 25) 19470-19474
15. Sumer E.U., Sondergaard B.C., Rousseau J.C., Delmas P.D., Fosang A.J., Karsdal M.A., et al. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 15 2 (2007 Feb) 212-221
16. Karsdal M.A., Sumer E.U., Wulf H., Madsen S.H., Christiansen C., Fosang A.J., et al. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum 56 5 (2007 May) 1549-1558
17. Karsdal M.A., Madsen S.H., Christiansen C., Henriksen K., Fosang A.J., and Sondergaard B.C. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 10 3 (2008) R63
18. Abramson S.B., Attur M., and Yazici Y. Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol 2 6 (2006 Jun) 304-312
19. Pelletier J.P., Martel-Pelletier J., and Abramson S.B. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 44 6 (2001 Jun) 1237-1247
20. Pelletier J.P., Roughley P.J., DiBattista J.A., McCollum R., and Martel-Pelletier J. Are cytokines involved in osteoarthritic pathophysiology?. Semin Arthritis Rheum 20 6 Suppl 2 (1991 Jun) 12-25
21. Fernandes J.C., Martel-Pelletier J., and Pelletier J.P. The role of cytokines in osteoarthritis pathophysiology. Biorheology 39 1-2 (2002) 237-246
22. Arend W.P. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 30 5 Suppl 2 (2001 Apr) 1-6
23. Arend W.P., and Dayer J.M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33 3 (1990 Mar) 305-315
24. Lawrence M.C., Jivan A., Shao C., Duan L., Goad D., Zaganjor E., et al. The roles of MAPKs in disease. Cell Res 18 4 (2008 Apr) 436-442
25. Karsdal M.A., Fjording M.S., Foged N.T., Delaisse J.M., and Lochter A. Transforming growth factor-beta-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J Biol Chem 276 42 (2001 Oct 19) 39350-39358
26. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 408 3 (2007 Dec 15) 297-315
27. Ishikawa T., Nishigaki F., Christgau S., Noto T., Mo J., From N., et al. Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J Rheumatol 31 6 (2004 Jun) 1174-1179
28. Karsdal M.A., Leeming D.J., Dam E.B., Henriksen K., Alexandersen P., Pastoureau P., et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 16 6 (2008 Jun) 638-646
29. Zhen E.Y., Brittain I.J., Laska D.A., Mitchell P.G., Sumer E.U., Karsdal M.A., et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 58 8 (2008 Aug) 2420-2431
30. Olsen A.K., Sondergaard B.C., Byrjalsen I., Tanko L.B., Christiansen C., Muller A., et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 15 3 (2007 Mar) 335-342
31. Charni-Ben T.N., Desmarais S., Bay-Jensen A.C., Delaisse J.M., Percival M.D., and Garnero P. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage 16 10 (2008 Oct) 1183-1191
32. Ridnour L.A., Windhausen A.N., Isenberg J.S., Yeung N., Thomas D.D., Vitek M.P., et al. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci USA 104 43 (2007 Oct 23) 16898-16903
33. Tortorella M.D., Liu R.Q., Burn T., Newton R.C., and Arner E. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol 21 6 (2002 Oct) 499-511
34. Hui W., Rowan A.D., Richards C.D., and Cawston T.E. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 48 12 (2003 Dec) 3404-3418
35. Lochter A., and Bissell M.J. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 107 (1999 Jan) 128-136
36. Karsdal M.A., Larsen L., Engsig M.T., Lou H., Ferreras M., Lochter A., et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277 46 (2002 Nov 15) 44061-44067
37. Liacini A., Sylvester J., Li W.Q., Huang W., Dehnade F., Ahmad M., et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 288 1 (2003 Aug 1) 208-217
38. Yoon S.W., Chun J.S., Sung M.H., Kim J.Y., and Poo H. Alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells. Osteoarthritis Cartilage 16 1 (2008 Jan) 115-124
39. Chen W.D., Jiang Q., Chen D.Y., Xu H., and Zhang Y.F. Effects of intra-articular injection of p38 mitogen-activated protein kinase inhibitor on matrix metalloproteinase in articular cartilage of a rat model of osteoarthritis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 29 6 (2007 Dec) 777-781
40. Ridley S.H., Sarsfield S.J., Lee J.C., Bigg H.F., Cawston T.E., Taylor D.J., et al. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol 158 7 (1997 Apr 1) 3165-3173
41. Mengshol J.A., Vincenti M.P., Coon C.I., Barchowsky A., and Brinckerhoff C.E. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 43 4 (2000 Apr) 801-811
42. El Mabrouk M., Sylvester J., and Zafarullah M. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochim Biophys Acta 1773 3 (2007 Mar) 309-320
43. Fan S., Meng Q., Laterra J.J., and Rosen E.M. Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem 284 12 (2009 Mar 20) 7561-7577
44. Pechkovsky D.V., Scaffidi A.K., Hackett T.L., Ballard J., Shaheen F., Thompson P.J., et al. Transforming growth factor beta1 induces alphavbeta3 integrin expression in human lung fibroblasts via a beta3 integrin-, c-Src-, and p38 MAPK-dependent pathway. J Biol Chem 283 19 (2008 May 9) 12898-12908